Company intelligence / Profile preview

Instance

Ownership: Private
Development stage: Other

Overview

Instance offers a next-generation synthetic biology platform focused on massively parallel, unbounded DNA pool synthesis. Their technology enables the creation of highly diverse and customizable pools of DNA fragments of any length (from tens to over 2000 base pairs), with no limitation on the number or diversity of sequences per pool. Each pool is NGS verified and shipped with detailed QC reports at the fragment level. The service is positioned as transformative for engineered biology at scale.

Modalities: DNA synthesis technology
Industry: Non-Drug Biotech

Beyond the preview

Go deeper on Instance.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Instance.

Explore the full profile